Christian Michael Horvath

Christian Michael Horvath

Auto-generated profile, based on publicly available information

Christian Michael Horvath

Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern , Bern

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Sleep Medicine Reviews
Verified
Journal Article
Open access
MBMathieu Berger
Mathieu Berger
GSGeoffroy Solelhac
Geoffroy Solelhac
CHChristian Horvath
Christian Horvath
RHRaphael Heinzer
Raphael Heinzer
ABAnne-Kathrin Brill
Anne-Kathrin Brill
This systematic review summarizes the prevalence of treatment-emergent central sleep apnea (TECSA) occurring with therapies other than positive airway pressure (PAP) for the management of obstructive sleep apnea (OSA). We describe its natural course as well as the proposed underlying pathophysiological mechanisms and the clinical management of affected patients. A systematic search of PubMed, Embase, Web of science, and the Cochrane Library was performed until June 2020. Eighteen studies (n = 284 patients) were included. TECSA was observed in 31 patients with the use of four different medical devices (mandibular advancement device, hypoglossal nerve stimulation, tongue stabilizing device and nasal expiratory PAP) and after three different types of surgical treatments (tracheostomy, maxillofacial surgery and oro-nasal surgery). Due to the paucity of data available, it was not possible to establish a clear prevalence rate of TECSA for each alternative treatment. After the initiation of non-PAP treatments, a systematic reassessment of the treatment efficacy with follow-up sleep studies will be helpful to identify TECSA. A spontaneous resolution over time was described as well as a persistence of TECSA. In this case, treatment should focus on patients' specific underlying pathophysiology. Overall, the limited current literature suggests that this phenomenon is rare (<4%).

22 August 2024 in Chest
Verified
Journal Article
Closed access
CHChristian M. Horvath
Christian M. Horvath
CFChristoph Fisser
Christoph Fisser
JFJohn S. Floras
John S. Floras
SSSamuel Sossalla
Samuel Sossalla
SWStella Wang
Stella Wang
MAMichael Arzt
Michael Arzt

26 November 2024 in Journal of Sleep Research
Verified
Journal Article
Closed access
MDMartijn Petrus Josephus Dekkers
Martijn Petrus Josephus Dekkers
CHChristian Michael Horvath
Christian Michael Horvath
VWVanessa S. Woerz
Vanessa S. Woerz
CBCorrado Bernasconi
Corrado Bernasconi
SDSimone B. Duss
Simone B. Duss
CBClaudio L. A. Bassetti
Claudio L. A. Bassetti

23 February 2025 in Journal of Sleep Research
Verified
Journal Article
Open access
CHChristian M. Horvath
Christian M. Horvath
HDHristina Drangova
Hristina Drangova
JSJakub Stefela
Jakub Stefela
CSCarolin Schäfer
Carolin Schäfer
FZFrederic Zubler
Frederic Zubler
The bidirectional interaction between sleep and epilepsy is well known. In particular, it has been established that sleep apnea can worsen epilepsy, whereas sleep apnea (SA) treatment has a beneficial effect on seizure control. However, the exact mechanisms whereby SA promotes epileptic seizures are unknown. We set out to examine whether interictal epileptic discharges (IED), one of the hallmarks of epilepsy, occur predominantly during respiratory events (RE, apnea or hypopnea) or desaturations in patients with obstructive SA (OSA) and epilepsy. Adult patients (> 18) who underwent a video‐polysomnography at the Bern University Hospital between 2012 and 2020 with an apnea‐hypopnea‐index (AHI) ≥ 10/h and IED were included in this retrospective study. IED density (per hour) was computed during and outside RE and oxygen desaturations (3%) using the AASM criteria and an extended definition. A total of 27 patients (9 females) met the inclusion criteria. The median age was 49 years and the median AHI was 17.4/h. There was no statistically significant difference in IED density in phases of sleep with RE compared to sleep without (median 3.6 [IQR 0.2–8.0] vs. 6.3 [3.7–19.7], p = 0.055). In the extended definition of RE, IED density was significantly lower during RE: 2.6 [0.3–6.6] versus 6.7 [3.9–20.5], p = 0.017. Desaturations were similarly associated with lower IED density in both analyses: 2.2 [0–7.4] versus 6.4 [3.4–18.4], p = 0.009 and 2.6 [0–6.7] versus 6.8 [3.4–18.5], p = 0.012. Our study shows that the influence of OSA on epileptic activity is probably indirect and does not result solely from immediate hypoxemia.

28 September 2019 in European Respiratory Journal
Verified
Conference Paper
Closed access
CHChristian Horvath
Christian Horvath
FBFlorent Baty
Florent Baty
CKChristian Kähler
Christian Kähler
Background: High flow nasal cannula therapy (HFNC) has been used in a variety of settings, e.g. hypoxemic respiratory failure in patients with interstitial lung disease or COPD, or as a possible alternative to non-invasive ventilation (NIV) in hypercapnic COPD. Only one long-term study has been carried out in hypoxemic COPD patients. Since insurance companies in Germany reimburse HFNC if NIV fails, we use this therapy regularly. Aims and Objective: We hypothesized that HFNV after NIV failure reduces long-term PaCO2. Methods: In a single center retrospective analysis, all patients after failure of NIV using HFNC were included from 2015 to 2018, irrespective of disease and exacerbation status. Data are reported as median with inter-quartile ranges. For all analyses, a p-value <0.05 was considered statistically significant. Results: 58 patients were identified, 27 had one inpatient control, 12 had outpatient control by the manufacturer, 22 died (median survival 99 days, 38-240) during the observation period, 23 were lost to follow-up before the first control, seven used NIV again, one patient required long term invasive ventilation. In hypercapnic patients with COPD (n=27), PaCO2 significantly diminished from 71 (62-77) mmHg before HFNC to 61 (58-67) mmHg after treatment (p<0.001) in hospital and at the first control compared to baseline (PaCO2 55 (49-64) mmHg) (n=12, p<0.024)). Conclusion: In a subset of patients after NIV failure, PaCO2 can be reduced long-term. Whether this translates to clinical meaningful differences is unclear. HFNC might be an alternative in this setting.

21 May 2022 in IJC Heart & Vasculature
Verified
Journal Article
Open access
CHChristian M. Horvath
Christian M. Horvath
CFChristoph Fisser
Christoph Fisser
TBT. Douglas Bradley
T. Douglas Bradley
JFJohn S. Floras
John S. Floras
SSSamuel Sossalla
Samuel Sossalla
MAMichael Arzt
Michael Arzt
Sleep disordered breathing (SDB) may trigger nocturnal cardiac arrhythmias (NCA) in patients with heart failure with reduced ejection fraction (HFrEF). The NCA ancillary study of the ADVENT-HF trial will test whether, in HFrEF-patients with SDB, peak-flow-triggered adaptive servo-ventilation (ASVpf) reduces NCA. To this end, accurate scoring of NCA from polysomnography (PSG) is required. To develop a method to detect NCA accurately from a single-lead electrocardiogram (ECG) recorded during PSG and assess inter-observer agreement for NCA detection. Quality assurance of ECG analysis included training of the investigators, development of standardized technical quality, guideline-conforming semi-automated NCA-scoring via Holter-ECG software and implementation of an arrhythmia adjudication committee. To assess inter-observer agreement, the ECG was analysed by two independent investigators and compared for agreement on premature ventricular complexes (PVC) /h, premature atrial complexes/h (PAC) as well as for other NCA in 62 patients from two centers of the ADVENT-HF trial. The intraclass correlation coefficients for PVC/h and PAC/h were excellent: 0.99 (95%- confidence interval [CI]: 0.99–0.99) and 0.99 (95%-CI: 0.97–0.99), respectively. No clinically relevant difference in inter-observer classification of other NCA was found. The detection of non-sustained ventricular tachycardia (18% versus 19%) and atrial fibrillation (10% versus 11%) was similar between the two investigators. No sustained ventricular tachycardia was detected. These findings indicate that our methods are very reliable for scoring NCAs and are adequate to apply for the entire PSG data set of the ADVENT-HF trial.